menu search

VYGR / Voyager: Recent Neurocrine Deal Signals More Upside

Voyager: Recent Neurocrine Deal Signals More Upside
In trying to deliver breakthrough, Voyager Therapeutics is able to ink multiple robust deals with reputable companies. The company is trying to tackle some of the most difficult to treat neurological conditions like Alzheimer's disease, ALS, and Parkinson's. Read More
Posted: Jan 14 2023, 04:19
Author Name: Seeking Alpha
Views: 101971

VYGR News  

Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?

By Zacks Investment Research
June 21, 2023

Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?

Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might more_horizontal

Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?

By Zacks Investment Research
May 4, 2023

Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisi more_horizontal

Voyager: Preclinical Company With Major Big Pharma Deals

By Seeking Alpha
April 2, 2023

Voyager: Preclinical Company With Major Big Pharma Deals

Voyager is a preclinical company with multibillion dollar big pharma deals. Its core asset is its TRACER AAV capsid delivery platform. more_horizontal

Voyager Therapeutics, Inc. (VYGR) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 7, 2023

Voyager Therapeutics, Inc. (VYGR) Q4 2022 Earnings Call Transcript

Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Al Sandrock - Chief Executive more_horizontal

Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates

By Zacks Investment Research
March 7, 2023

Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -7.02% and 112.20%, respectively, for the quarter ended December 2022. Do the more_horizontal

3 Best Stocks to Invest in for Remarkable Earnings Acceleration

By Zacks Investment Research
February 10, 2023

3 Best Stocks to Invest in for Remarkable Earnings Acceleration

Some of the notable companies to have witnessed solid earnings acceleration as of now are Las Vegas Sands (LVS), Voyager Therapeutics (VYGR) & nCino ( more_horizontal

Why Voyager Therapeutics Stock Is Sinking This Week

By The Motley Fool
January 20, 2023

Why Voyager Therapeutics Stock Is Sinking This Week

Investors are taking profits on this red-hot stock this week. more_horizontal

Voyager: Recent Neurocrine Deal Signals More Upside

By Seeking Alpha
January 14, 2023

Voyager: Recent Neurocrine Deal Signals More Upside

In trying to deliver breakthrough, Voyager Therapeutics is able to ink multiple robust deals with reputable companies. The company is trying to tackle more_horizontal


Search within

Pages Search Results: